The National University of Singapore (NUS) has emerged as a pivotal force in addressing one of the most pressing global health challenges: antimicrobial resistance (AMR). As bacteria evolve to withstand antibiotics—the life-saving drugs discovered in the early 20th century that revolutionized medicine—NUS researchers are leading efforts to curb misuse and overuse of these medications. In Singapore, where high antibiotic consumption in hospitals and communities fuels resistance, NUS's Yong Loo Lin School of Medicine and Saw Swee Hock School of Public Health are at the forefront, advocating for robust stewardship programs and innovative research to safeguard public health.

AMR occurs when microorganisms such as bacteria, viruses, fungi, and parasites change over time and no longer respond to drugs designed to kill them, rendering standard treatments ineffective. This phenomenon, often called the 'silent pandemic,' claimed 1.27 million direct deaths worldwide in 2019 alone, according to World Health Organization (WHO) estimates, with projections soaring to 10 million annually by 2050 if unchecked. In Singapore, up to 50% of hospital-acquired infections resist frontline antibiotics, highlighting the urgency. NUS experts emphasize that preventing misuse—such as prescribing antibiotics for viral infections like the common cold or flu—is key to slowing this crisis.

Recent developments underscore NUS's proactive stance. A landmark study published in early 2026 by NUS Medicine researchers illuminated how resistance genes transfer from harmless gut bacteria to dangerous hospital pathogens like hypervirulent Klebsiella pneumoniae, a superbug notorious for severe infections. This discovery stresses the need for targeted interventions in gut health and antibiotic prescribing to block transmission pathways.

Understanding the Roots of Antibiotics Misuse in Singapore

Antibiotics, first introduced with penicillin in 1928 by Alexander Fleming, target bacterial infections by disrupting cell walls, protein synthesis, or DNA replication. However, misuse accelerates resistance through natural selection: surviving bacteria multiply, passing on resistant traits via mutations or horizontal gene transfer—where DNA segments 'jump' between microbes, even across species.

In Singapore, factors driving misuse include patient demand for quick fixes, overprescription in primary care (up to 30% unnecessary per local audits), and agricultural use in livestock. Hospitals report rising carbapenem-resistant Enterobacteriaceae (CRE), with incidence climbing 20% in recent years. NUS public health experts note that dense urban living and international travel exacerbate spread, making stewardship—systematic efforts to optimize antibiotic selection, dose, and duration—essential.

Cultural context matters: Singaporeans' high health literacy contrasts with persistent beliefs that antibiotics cure all illnesses. NUS-led surveys reveal 40% of respondents expect antibiotics for colds, perpetuating the cycle.

NUS's Pioneering Research on AMR Transmission

Led by Principal Investigator Assistant Professor Pei-Yun Hon at NUS Medicine's Department of Medicine, the 2026 study analyzed patient stool samples and hospital isolates, revealing plasmids—mobile DNA carriers—as key vectors for resistance genes like those for extended-spectrum beta-lactamases (ESBL). These genes, common in community guts due to prior antibiotic exposure, hitchhike to virulent strains in immunocompromised patients.

"Our findings highlight a hidden reservoir in the human gut fueling hospital superbugs," Hon stated. The research used metagenomic sequencing to track gene flow, showing 25% of resistant hospital Klebsiella matched community plasmids. Implications? Routine gut microbiome screening and probiotics could disrupt this pipeline.

This builds on NUS's CoSTAR-HS (Collaborative Solutions Targeting Antimicrobial Resistance Threats in Health Systems), funded in 2016, which develops primary care interventions to cut inappropriate prescriptions by 15-20% through clinician training and decision tools.

Singapore's National Action Plan: NUS's Integral Role

Singapore's National Strategic Action Plan on AMR (NSAP) 2.0, launched November 2025, outlines five pillars: awareness, surveillance, research, infection control, and stewardship. NUS evaluated the original 2017-2023 plan, identifying gaps in coordination and behavior change, directly shaping v2.0's targets like stewardship in all acute hospitals by 2030 and prescription-only veterinary antibiotics.

NUS contributes via the Health Intervention and Policy Evaluation Research (HIPER) unit, analyzing NAP progress. Prof Hsu Li-Yang, SSHSPH, advises on policy, stressing integrated One Health surveillance—linking human, animal, and environmental data.

Progress: Fluoroquinolone farm sales dropped 30% post-NSAP, but human misuse persists, with 25% primary care antibiotics avoidable.

Photo by Kaden Taylor on Unsplash

NUS Training the Next Generation of Stewardship Champions

As Singapore's premier medical school, NUS integrates AMR into curricula. Yong Loo Lin School's antimicrobial stewardship module teaches Year 3 students via simulations: diagnosing viral vs bacterial infections, calculating doses, and debating ethics. "Future doctors must lead change," says Dr. Alvin Chua, who co-leads regional workshops.

Programs like the Singapore Antimicrobial Stewardship Training Course, hosted by NUS affiliates, train 200+ clinicians yearly. Duke-NUS collaboration yields PhD theses on stewardship economics, estimating S$50M annual AMR costs in Singapore.

Stakeholder Perspectives: From Hospitals to Farms

Hospitals like NUH implement NUS-guided audits, reducing broad-spectrum use 12%. Vets push biosecurity over prophylactics. Public campaigns, informed by NUS surveys, use apps tracking symptoms to deter self-demand.

Farmers cite cost barriers, but NUS aquaculture studies show phage therapy—viruses killing bacteria—as viable alternatives, cutting antibiotics 40% in trials.

Challenges: Multi-drug resistance in 15% ICU cases; solutions include rapid diagnostics NUS is piloting.

Innovations Emerging from NUS Labs

Beyond stewardship, NUS pioneers tech. Liu Bin's TPA2PyBu disrupts bacterial membranes, effective against resistant strains. Guillermo Bazan's COE platform targets mycobacteria. UV-LED disinfection from Civil Engineering curbs environmental ARGs.

AI models predict resistance patterns, aiding prescribing. These align with NSAP's research pillar, positioning NUS as Asia-Pacific hub.

Real-World Impacts and Case Studies

• NUH Stewardship: Post-NUS intervention, Clostridium difficile infections fell 22% via narrow-spectrum shifts.
• Primary Care Pilot: NUS-CoSTAR app reduced prescriptions 18% in polyclinics.
• Vet Sector: SFA-NUS monitoring halved colistin use.

Timeline: 2017 NAP launch; 2021 One Health Report; 2025 v2.0; 2026 NUS gut-AMR study accelerates action.

Photo by Sean Seah on Unsplash

Challenges and Future Outlook

Barriers: Aging population boosts infections; climate change may worsen via floods spreading ARGs. NUS calls for market incentives—pull-funding new antibiotics—as science alone falters.

Outlook: By 2030, NSAP targets 10% fewer resistant infections. NUS envisions AI diagnostics, phage banks, microbiome therapies. For higher ed, expanded AMR modules prepare grads for global roles.

Actionable Insights for Stakeholders

• Clinicians: Use point-of-care tests; follow NUS guidelines.
• Students: Engage NUS electives on One Health.
• Public: Complete courses; report symptoms accurately.
• Policy: Fund NUS-like research S$100M/year.

NUS's call resonates: Strengthen measures now to avert crisis. As Prof Hsu notes, "AMR demands multidisciplinary action—universities like NUS bridge research to policy."